Immatics (NASDAQ:IMTXW – Get Free Report) shares dropped 14.1% during trading on Monday . The stock traded as low as $0.77 and last traded at $0.85. Approximately 5,304 shares changed hands during trading, a decline of 31% from the average daily volume of 7,647 shares. The stock had previously closed at $0.99.
Immatics Stock Performance
The firm’s fifty day simple moving average is $1.78 and its 200 day simple moving average is $2.46.
About Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Featured Stories
- Five stocks we like better than Immatics
- Technology Stocks Explained: Here’s What to Know About Tech
- Rocket Lab is the Right Stock for the Right Time
- Investing in Travel Stocks Benefits
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Financial Services Stocks Investing
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.
